Literature DB >> 33804064

Epstein-Barr Virus LMP1 Induces Soluble PD-L1 in Nasopharyngeal Carcinoma.

Kina Kase1, Satoru Kondo1, Naohiro Wakisaka1, Hirotomo Dochi1, Harue Mizokami1, Eiji Kobayashi1, Makoto Kano1, Takeshi Komori1, Nobuyuki Hirai1, Takayoshi Ueno1, Yosuke Nakanishi1, Miyako Hatano1, Kazuhira Endo1, Makiko Moriyama-Kita1, Hisashi Sugimoto1, Tomokazu Yoshizaki1.   

Abstract

Nasopharyngeal carcinoma (NPC) is an Epstein-Barr virus (EBV)-associated malignancy. The principal oncogene of EBV, latent membrane protein 1 (LMP1), induces the expression of programmed death-ligand 1 (PD-L1), which is an immunosuppressive transmembrane protein and a promising therapeutic target for various malignancies. Recent studies have revealed an association between the level of soluble PD-L1 (sPD-L1) and disease progression. However, the role of sPD-L1 in NPC or its relevance to LMP1 has not been elucidated. This study aimed to examine whether LMP1 induces sPD-L1 in vitro and analyze the clinical relevance of LMP1, PD-L1, and sPD-L1 in NPC patients. Analysis of nasopharyngeal cell lines revealed that LMP1 induces both cellular PD-L1 and sPD-L1. Analysis of biopsy specimens from 32 NPC patients revealed that LMP1 expression was significantly correlated with PD-L1 expression. Finally, the serum sPD-L1 level in NPC patients was higher than that in the controls. Moreover, the sPD-L1 level in the advanced stage was higher than that in the early stage. However, LMP1 expression, PD-L1 expression, and sPD-L1 levels were not associated with prognosis. These results suggest that LMP1 induces both sPD-L1 and PD-L1, which are associated with NPC progression.

Entities:  

Keywords:  EBV; LMP1; PD-L1; nasopharyngeal carcinoma; sPD-L1

Year:  2021        PMID: 33804064      PMCID: PMC7998736          DOI: 10.3390/microorganisms9030603

Source DB:  PubMed          Journal:  Microorganisms        ISSN: 2076-2607


  43 in total

1.  Discerning regulation of cis- and trans-presentation of CD8+ T-cell epitopes by EBV-encoded oncogene LMP-1 through self-aggregation.

Authors:  Corey Smith; Naohiro Wakisaka; Tania Crough; Jesse Peet; Tomokazu Yoshizaki; Leone Beagley; Rajiv Khanna
Journal:  Blood       Date:  2009-04-16       Impact factor: 22.113

2.  Overexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers.

Authors:  Juro Nakanishi; Yoshihiro Wada; Koichiro Matsumoto; Miyuki Azuma; Ken Kikuchi; Shoichi Ueda
Journal:  Cancer Immunol Immunother       Date:  2006-12-22       Impact factor: 6.968

3.  B7-h4 is a novel membrane-bound protein and a candidate serum and tissue biomarker for ovarian cancer.

Authors:  Iris Simon; Shaoqiu Zhuo; Laura Corral; Eleftherios P Diamandis; Mark J Sarno; Robert L Wolfert; Nam W Kim
Journal:  Cancer Res       Date:  2006-02-01       Impact factor: 12.701

4.  Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial.

Authors:  Li Zhang; Yan Huang; Shaodong Hong; Yunpeng Yang; Gengsheng Yu; Jun Jia; Peijian Peng; Xuan Wu; Qing Lin; Xuping Xi; Jiewen Peng; Mingjun Xu; Dongping Chen; Xiaojun Lu; Rensheng Wang; Xiaolong Cao; Xiaozhong Chen; Zhixiong Lin; Jianping Xiong; Qin Lin; Conghua Xie; Zhihua Li; Jianji Pan; Jingao Li; Shixiu Wu; Yingni Lian; Quanlie Yang; Chong Zhao
Journal:  Lancet       Date:  2016-08-23       Impact factor: 79.321

5.  Soluble programmed death-ligand 1 (sPDL1) and neutrophil-to-lymphocyte ratio (NLR) predicts survival in advanced biliary tract cancer patients treated with palliative chemotherapy.

Authors:  Hyerim Ha; Ah-Rong Nam; Ju-Hee Bang; Ji-Eun Park; Tae-Yong Kim; Kyung-Hun Lee; Sae-Won Han; Seock-Ah Im; Tae-You Kim; Yung-Jue Bang; Do-Youn Oh
Journal:  Oncotarget       Date:  2016-11-22

6.  Secreted PD-L1 variants mediate resistance to PD-L1 blockade therapy in non-small cell lung cancer.

Authors:  Bo Gong; Kazuma Kiyotani; Seiji Sakata; Seiji Nagano; Shun Kumehara; Satoko Baba; Benjamin Besse; Noriko Yanagitani; Luc Friboulet; Makoto Nishio; Kengo Takeuchi; Hiroshi Kawamoto; Naoya Fujita; Ryohei Katayama
Journal:  J Exp Med       Date:  2019-03-14       Impact factor: 14.307

7.  Comparative safety and efficacy of anti-PD-1 monotherapy, chemotherapy alone, and their combination therapy in advanced nasopharyngeal carcinoma: findings from recent advances in landmark trials.

Authors:  Jia-Wei Lv; Jun-Yan Li; Lin-Na Luo; Zi-Xian Wang; Yu-Pei Chen
Journal:  J Immunother Cancer       Date:  2019-06-25       Impact factor: 13.751

Review 8.  Modulation of the tumor microenvironment by Epstein-Barr virus latent membrane protein 1 in nasopharyngeal carcinoma.

Authors:  Tomokazu Yoshizaki; Satoru Kondo; Kazuhira Endo; Yosuke Nakanishi; Mitsuharu Aga; Eiji Kobayashi; Nobuyuki Hirai; Hisashi Sugimoto; Miyako Hatano; Takayoshi Ueno; Kazuya Ishikawa; Naohiro Wakisaka
Journal:  Cancer Sci       Date:  2018-01-21       Impact factor: 6.716

9.  Soluble PD-L1: A biomarker to predict progression of autologous transplantation in patients with multiple myeloma.

Authors:  Shang-Yi Huang; Hsiu-Hsia Lin; Chung-Wu Lin; Chi-Cheng Li; Ming Yao; Jih-Luh Tang; Hsin-An Hou; Woei Tsay; Sheng-Je Chou; Chieh-Lung Cheng; Hwei-Fang Tien
Journal:  Oncotarget       Date:  2016-09-20

10.  Association between serum level soluble programmed cell death ligand 1 and prognosis in patients with non-small cell lung cancer treated with anti-PD-1 antibody.

Authors:  Shuji Murakami; Ryota Shibaki; Yuji Matsumoto; Tatsuya Yoshida; Yasushi Goto; Shintaro Kanda; Hidehito Horinouchi; Yutaka Fujiwara; Noboru Yamamoto; Yuichiro Ohe
Journal:  Thorac Cancer       Date:  2020-10-27       Impact factor: 3.500

View more
  1 in total

Review 1.  Prognostic value of PD-1, PD-L1 and PD-L2 deserves attention in head and neck cancer.

Authors:  Siqing Jiang; Xin Li; Lihua Huang; Zhensheng Xu; Jinguan Lin
Journal:  Front Immunol       Date:  2022-09-02       Impact factor: 8.786

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.